Moberg Pharma’s MOB-015 Nail Fungus Treatment Fails to Achieve Primary Outcome in Phase 3, Says Cipher Pharma
Cipher Pharmaceuticals Inc., a company specializing in pharmaceuticals and boasting a wide range of commercialized as well as early to advanced stage products, has disclosed that its collaborator, Moberg Pharma AB, has released a statement indicating that MOB-015, a treatment […]